Compare COUR & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COUR | BCYC |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 516.8M |
| IPO Year | 2021 | 2019 |
| Metric | COUR | BCYC |
|---|---|---|
| Price | $7.56 | $6.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | $12.33 | ★ $18.73 |
| AVG Volume (30 Days) | ★ 3.7M | 281.9K |
| Earning Date | 01-29-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $739,774,000.00 | $28,339,000.00 |
| Revenue This Year | $10.46 | N/A |
| Revenue Next Year | $6.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.09 | N/A |
| 52 Week Low | $5.76 | $6.03 |
| 52 Week High | $13.56 | $17.04 |
| Indicator | COUR | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 35.88 | 45.49 |
| Support Level | $7.83 | $7.03 |
| Resistance Level | $8.89 | $7.50 |
| Average True Range (ATR) | 0.37 | 0.36 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 6.99 | 15.22 |
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.